Inmed reports first quarter fiscal 2025 financial results and provides business update

Vancouver, british columbia--(newsfile corp. - november 14, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the first quarter of the fiscal year 2025 which ended september 30, 2024. the company's full financial statements and related md&a for the first quarter ended september 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
INM Ratings Summary
INM Quant Ranking